The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Pls calm down
Read the rns - This is not a figure that relates to the potential output from Omega and its manufacturing facilities alone.
IE - EVEN Mologic cant manage that number alone at 50. Merely going to outsource to another manufacturer under license I'm sure. So if I am reading it the same as others that simply means 50M WILL BE MADE X £10 per test. Its still happening here
even
Regulatory Story
Go to market news section View chart Print
RNS Omega Diagnostics Group PLC - ODX
Stmnt re Share Price Movement
Released 15:53 27-May-2020
RNS Number : 1226O
Omega Diagnostics Group PLC
27 May 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Statement regarding share price movement
Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, notes the recent rise in the Company's share price and confirms that it is not aware of any material reason for the significant increase.
As previously announced the Company continues to work with its partner Mologic Ltd with regards its first generation ELISA antibody test for COVID-19 and also with the UK Rapid Test Consortium, which is jointly developing, and will manufacture, a Point-of-Care COVID-19 lateral flow antibody test.
In respect of both these opportunities the Company will keep the market informed as matters develop.
In a Sky News interview earlier today, the introduction referred to the Consortium being able to make 50m tests a year, a figure also referred to in a newspaper article published on 26 April 2020. This is not a figure that relates to the potential output from Omega and its manufacturing facilities alone.
Contacts:
Omega Diagnostics Group PLC
Tel: 01259 763 030
Bill Rhodes, Interim Non-Executive Chairman
Colin King, Chief Executive
www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd
Tel: 020 7220 0500
Geoff Nash/Hannah Boros (Corporate Finance)
Camille Gochez (ECM)
Walbrook PR Limited
Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus
Mob: 07980 541 893
Lianne Cawthorne
Mob: 07584 391 303
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
SPMEALSXASFEEFA
CLOSE
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.
©2014 London Stock Exchange plc. All rights reserved
Stmnt re Share Price Movement - RNS
Can someone post it